Prosensa Holdings is Now Oversold (RNA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Friday, shares of Prosensa Holdings N.V. ( RNA) entered into oversold territory, hitting an RSI reading of 27.7, after changing hands as low as $5.50 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 53.1. A bullish investor could look at RNA's 27.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of RNA shares:

START SLIDESHOW:
Find out what 9 other oversold stocks you need to know about »

Prosensa Holdings N.V. 1 Year Performance Chart

Looking at the chart above, RNA's low point in its 52 week range is $3.43 per share, with $34.55 as the 52 week high point — that compares with a last trade of $5.51.

If you liked this article you might like

Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year

Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains

Prosensa Holding (RNA) Upgraded From Sell to Hold

The Nominees for Best Biotechnology Co. CEO of 2014 Are...

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta